|
US20030044384A1
(en)
*
|
1997-10-09 |
2003-03-06 |
Pro-Virus, Inc. |
Treatment of neoplasms with viruses
|
|
BR0015491A
(pt)
|
1999-11-12 |
2002-10-15 |
Oncolytics Biotech Inc |
Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
|
|
AUPQ425699A0
(en)
|
1999-11-25 |
1999-12-23 |
University Of Newcastle Research Associates Limited, The |
A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
|
|
EP1244469A2
(en)
*
|
1999-12-08 |
2002-10-02 |
Onyx Pharmaceuticals, Inc. |
Mutant simplex virus for treating unwanted hyperproliferative cell growth
|
|
AR028039A1
(es)
|
2000-05-03 |
2003-04-23 |
Oncolytics Biotech Inc |
Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
|
|
US8491884B2
(en)
|
2000-05-03 |
2013-07-23 |
Oncolytics Biotech Inc. |
Virus clearance of neoplastic cells from mixed cellular compositions
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
AR028040A1
(es)
*
|
2000-05-03 |
2003-04-23 |
Oncolytics Biotech Inc |
Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
|
|
US20020156039A1
(en)
*
|
2000-07-07 |
2002-10-24 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using Sal2
|
|
US20050013803A1
(en)
*
|
2000-07-07 |
2005-01-20 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using mutant viruses
|
|
US20030157481A1
(en)
*
|
2001-12-10 |
2003-08-21 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using T-HR mutants and their targets
|
|
US20020147996A1
(en)
*
|
2000-07-07 |
2002-10-10 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using Sal2
|
|
US6982251B2
(en)
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
DK1355644T3
(da)
|
2001-01-26 |
2006-10-23 |
Schering Corp |
Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
|
|
HU230253B1
(hu)
|
2001-01-26 |
2015-11-30 |
Merck Sharp & Dohme Corp |
Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
|
|
US7071181B2
(en)
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
AR035227A1
(es)
*
|
2001-02-20 |
2004-05-05 |
Oncolytics Biotech Inc |
Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
|
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
US7053080B2
(en)
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
JP2005504091A
(ja)
|
2001-09-21 |
2005-02-10 |
シェーリング コーポレイション |
ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
|
|
AU2002353031A1
(en)
*
|
2001-12-07 |
2003-06-23 |
Bayer Corporation |
Use of parapox b2l protein to treat cancer and modify immune responses
|
|
WO2003080083A1
(es)
*
|
2002-03-26 |
2003-10-02 |
Oncolytics Biotech Inc. |
Uso de adenovirus mutados en los genes va para el tratamiento del cancer
|
|
AU2003223686A1
(en)
*
|
2002-04-26 |
2003-11-10 |
Wellstat Biologics Corporation |
Immunogenic agent therapy using plasmapheresis or exchange transfusion
|
|
US20040180438A1
(en)
*
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
|
AU2003249059A1
(en)
|
2002-07-24 |
2004-02-09 |
Arizona Board Of Regents |
Use of vaccinia virus deleted for the e3l gene as a vaccine vector
|
|
KR20120002613A
(ko)
|
2002-08-12 |
2012-01-06 |
제네렉스, 인코포레이티드 |
폭스바이러스 및 암과 관련된 방법 및 조성물
|
|
WO2004043457A1
(en)
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
|
AU2002953436A0
(en)
|
2002-12-18 |
2003-01-09 |
The University Of Newcastle Research Associates Limited |
A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
|
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
CA2517571C
(en)
|
2003-03-07 |
2011-07-05 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
JP2006519869A
(ja)
|
2003-03-07 |
2006-08-31 |
シェーリング コーポレイション |
置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
|
|
JP4589919B2
(ja)
|
2003-03-07 |
2010-12-01 |
シェーリング コーポレイション |
高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
|
|
ATE420160T1
(de)
|
2003-06-18 |
2009-01-15 |
Genelux Corp |
Modifizierte rekombinante vacciniaviren, verwendungen davon
|
|
WO2005007824A2
(en)
*
|
2003-07-08 |
2005-01-27 |
Arizona Board Of Regents |
Mutants of vaccinia virus as oncolytic agents
|
|
US7442372B2
(en)
|
2003-08-29 |
2008-10-28 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
|
WO2006031996A2
(en)
*
|
2004-09-14 |
2006-03-23 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Targeting viruses using a modified sindbis glycoprotein
|
|
WO2006071966A2
(en)
*
|
2004-12-29 |
2006-07-06 |
The Brigham And Women's Hospital, Inc. |
Rapamycin compounds in the treatment of neurofibromatosis type 1
|
|
UA100836C2
(ru)
|
2005-02-23 |
2013-02-11 |
Бавариан Нордик А/С |
Применение модифицированного вируса осповакцины анкара (mva) для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов
|
|
US20090035276A1
(en)
*
|
2005-03-07 |
2009-02-05 |
Robarts Research Institute |
Use of a combination of myxoma virus and rapamycin for therapeutic treatment
|
|
US20070004767A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Gutmann David H |
Methods for treating neurofibromatosis 1
|
|
US10260049B2
(en)
|
2005-08-01 |
2019-04-16 |
Virocure, Inc. |
Attenuated reovirus
|
|
US10668119B2
(en)
|
2005-08-01 |
2020-06-02 |
Virocure, Inc. |
Attenuated reovirus
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
KR101772375B1
(ko)
|
2005-09-07 |
2017-08-29 |
신라젠(주) |
Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
|
|
ES2551306T3
(es)
*
|
2006-02-13 |
2015-11-17 |
Oncolytics Biotech Inc. |
Uso de inmunosupresión local de baja dosis para potenciar una terapia viral oncolítica
|
|
EP2097517B1
(en)
|
2006-10-16 |
2014-06-04 |
Genelux Corporation |
Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
|
|
US10369171B2
(en)
|
2007-03-13 |
2019-08-06 |
Virocure, Inc. |
Attenuated reoviruses for selection of cell populations
|
|
CA2690627C
(en)
|
2007-06-15 |
2014-12-02 |
Genelux Corporation |
Microorganisms for imaging and/or treatment of tumors
|
|
JP2010533718A
(ja)
*
|
2007-07-18 |
2010-10-28 |
ジェネラックス・コーポレイション |
腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
|
|
WO2009135614A2
(en)
*
|
2008-05-09 |
2009-11-12 |
Bayer Schering Pharma Aktiengesellschaft |
Use of a virus regimen for the treatment of diseases
|
|
US20120052003A9
(en)
*
|
2008-05-16 |
2012-03-01 |
Szalay Aladar A |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
EP2296678A4
(en)
*
|
2008-05-27 |
2012-03-21 |
Oncolytics Biotech Inc |
MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION
|
|
ES2645692T3
(es)
|
2008-11-11 |
2017-12-07 |
The Board Of Regents,The University Of Texas System |
Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
|
|
ES2848650T3
(es)
|
2009-09-14 |
2021-08-11 |
Sillajen Biotherapeutics Inc |
Terapia combinada contra el cáncer con virus vaccinia oncolítico
|
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
|
AU2012204467B2
(en)
|
2011-01-04 |
2016-08-18 |
Sillajen, Inc. |
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
|
|
WO2012122649A1
(en)
*
|
2011-03-15 |
2012-09-20 |
Ottawa Hospital Research Institute |
Recombinant orf virus
|
|
ES2733211T3
(es)
|
2011-04-15 |
2019-11-28 |
Genelux Corp |
Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
|
|
WO2013052915A2
(en)
|
2011-10-05 |
2013-04-11 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
WO2014160328A1
(en)
|
2013-03-13 |
2014-10-02 |
The Board Of Regents Of The University Of Texas System |
Mtor inhibitors for prevention of intestinal polyp growth
|
|
SG11201507393TA
(en)
|
2013-03-14 |
2015-10-29 |
Salk Inst For Biological Studi |
Oncolytic adenovirus compositions
|
|
DE102013105144A1
(de)
*
|
2013-05-17 |
2014-11-20 |
Arno Thaller |
Pharmazeutisches Kombinationspräparat mit einem anti-idiotypischen Antikörperfragment
|
|
EP3089737B1
(en)
|
2013-12-31 |
2021-11-03 |
Rapamycin Holdings, LLC |
Oral rapamycin nanoparticle preparations and use
|
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
|
KR102608590B1
(ko)
|
2014-09-24 |
2023-12-01 |
솔크 인스티튜트 포 바이올로지칼 스터디즈 |
종양 살상 바이러스 및 이의 사용방법
|
|
AU2015335607B2
(en)
|
2014-10-24 |
2020-04-23 |
Calidi Biotherapeutics (Nevada), Inc. |
Combination immunotherapy approach for treatment of cancer
|
|
CN115300622A
(zh)
|
2015-02-25 |
2022-11-08 |
纪念斯隆-凯特琳癌症中心 |
使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
|
|
CN107847534B
(zh)
|
2015-04-17 |
2022-10-04 |
纪念斯隆凯特琳癌症中心 |
Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
|
|
CN108135996B
(zh)
|
2015-08-11 |
2022-06-21 |
卡利迪生物治疗有限公司 |
用以癌症治疗的天花疫苗
|
|
US10612005B2
(en)
|
2016-01-08 |
2020-04-07 |
Replimune Limited |
Modified oncolytic virus
|
|
CN105754952B
(zh)
*
|
2016-02-16 |
2020-07-10 |
中国农业科学院兰州兽医研究所 |
抗羊痘病毒k3l蛋白c末端的单克隆抗体及其应用
|
|
WO2017147269A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
|
|
WO2017147265A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
High throughput assay for measuring adenovirus replication kinetics
|
|
IL261321B2
(en)
|
2016-02-25 |
2023-12-01 |
Memorial Sloan Kettering Cancer Center |
Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
|
|
KR20180133395A
(ko)
|
2016-02-25 |
2018-12-14 |
메모리얼 슬로안 케터링 캔서 센터 |
암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스
|
|
CN109152736A
(zh)
*
|
2016-03-25 |
2019-01-04 |
联邦高等教育系统匹兹堡大学 |
合成包封病毒
|
|
WO2017205674A1
(en)
*
|
2016-05-25 |
2017-11-30 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Oncolytic vaccinia virus mutants and using same for cancer treatment
|
|
AU2017299983B2
(en)
*
|
2016-07-21 |
2021-01-07 |
Kolon Life Science, Inc. |
Recombinant vaccinia virus and use thereof
|
|
EP3532082A4
(en)
|
2016-12-12 |
2020-08-26 |
Salk Institute for Biological Studies |
SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
WO2018209315A1
(en)
|
2017-05-12 |
2018-11-15 |
Memorial Sloan Kettering Cancer Center |
Vaccinia virus mutants useful for cancer immunotherapy
|
|
US10610583B2
(en)
|
2017-08-31 |
2020-04-07 |
Regents Of The University Of Minnesota |
Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
|
|
BR112020014727A2
(pt)
*
|
2018-01-19 |
2020-12-08 |
Kolon Life Science, Inc. |
Vírus vaccinia recombinante e composição farmacêutica compreendendo o mesmo
|
|
CN112292449A
(zh)
|
2018-04-09 |
2021-01-29 |
萨克生物研究学院 |
具有增强的复制特性的溶瘤腺病毒组合物
|
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
MX2021003013A
(es)
|
2018-09-15 |
2021-08-11 |
Memorial Sloan Kettering Cancer Center |
Poxvirus recombinantes para inmunoterapia contra cáncer.
|
|
CN114364390A
(zh)
*
|
2019-08-26 |
2022-04-15 |
拜耳诺克斯有限公司 |
用于治疗癌症的包含抗癌病毒、免疫检查点抑制剂和羟基脲作为活性成分的药物组合物
|